DOP2014000133A - Triazolopiridinas sustituidas - Google Patents

Triazolopiridinas sustituidas

Info

Publication number
DOP2014000133A
DOP2014000133A DO2014000133A DO2014000133A DOP2014000133A DO P2014000133 A DOP2014000133 A DO P2014000133A DO 2014000133 A DO2014000133 A DO 2014000133A DO 2014000133 A DO2014000133 A DO 2014000133A DO P2014000133 A DOP2014000133 A DO P2014000133A
Authority
DO
Dominican Republic
Prior art keywords
compounds
substituted
triazolopiridins
preparing
triazolpyridine
Prior art date
Application number
DO2014000133A
Other languages
English (en)
Inventor
Dirk Kosemund
Volker Schulze
Gerhard Siemeister
Antje Margret Wengner
Detlef Stöckigt
Michael Bruening
Original Assignee
Bayer Pharma AG
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG, Bayer Ip Gmbh filed Critical Bayer Pharma AG
Publication of DOP2014000133A publication Critical patent/DOP2014000133A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Compuestos de triazolpiridina sustituida de la fórmula general (I) donde R1, R2, R3, R4 y R5 tienen los valores que se definen en la descripción y en las reivindicaciones. Métodos para preparar dichos compuestos. Composiciones y combinaciones farmacéuticas que comprenden dichos compues-tos. Uso de dichos compuestos para preparar una composición farmacéutica para el tratamiento o la profilaxis de una enfermedad. Compuestos interme-diarios útiles para preparar dichos compuestos.
DO2014000133A 2011-12-12 2014-06-12 Triazolopiridinas sustituidas DOP2014000133A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP11193011 2011-12-12

Publications (1)

Publication Number Publication Date
DOP2014000133A true DOP2014000133A (es) 2014-07-31

Family

ID=47427291

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2014000133A DOP2014000133A (es) 2011-12-12 2014-06-12 Triazolopiridinas sustituidas

Country Status (40)

Country Link
US (1) US9663510B2 (es)
EP (1) EP2791136B1 (es)
JP (1) JP6181664B2 (es)
KR (1) KR20140105552A (es)
CN (1) CN104114552B (es)
AP (1) AP4017A (es)
AR (1) AR089143A1 (es)
AU (1) AU2012350751B2 (es)
BR (1) BR112014014184A2 (es)
CA (1) CA2858683A1 (es)
CL (1) CL2014001546A1 (es)
CO (1) CO6980657A2 (es)
CR (1) CR20140275A (es)
CU (1) CU20140068A7 (es)
CY (1) CY1116958T1 (es)
DK (1) DK2791136T3 (es)
DO (1) DOP2014000133A (es)
EC (1) ECSP14004812A (es)
ES (1) ES2550677T3 (es)
GT (1) GT201400111A (es)
HK (1) HK1203200A1 (es)
HR (1) HRP20151103T1 (es)
HU (1) HUE025937T2 (es)
IL (1) IL232930A (es)
JO (1) JO3111B1 (es)
MA (1) MA35826B1 (es)
MX (1) MX2014007057A (es)
PE (1) PE20141597A1 (es)
PH (1) PH12014501319A1 (es)
PL (1) PL2791136T3 (es)
PT (1) PT2791136E (es)
RS (1) RS54288B1 (es)
RU (1) RU2632464C1 (es)
SG (1) SG11201402820SA (es)
SI (1) SI2791136T1 (es)
TN (1) TN2014000254A1 (es)
UA (1) UA112096C2 (es)
UY (1) UY34515A (es)
WO (1) WO2013087579A1 (es)
ZA (1) ZA201404031B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201408419QA (en) * 2012-07-10 2015-01-29 Bayer Pharma AG Method for preparing substituted triazolopyridines
WO2014020041A1 (en) 2012-08-02 2014-02-06 Bayer Pharma Aktiengesellschaft Combinations for the treatment of cancer
WO2014020043A1 (en) 2012-08-02 2014-02-06 Bayer Pharma Aktiengesellschaft Combinations for the treatment of cancer
AR096469A1 (es) * 2013-06-06 2015-12-30 Bayer Pharma AG Composiciones farmacéuticas que comprenden compuestos del tipo triazolpiridinas
SG11201509858QA (en) * 2013-06-11 2015-12-30 Bayer Pharma AG Prodrug derivatives of substituted triazolopyridines
SG11201509350RA (en) * 2013-06-11 2015-12-30 Bayer Pharma AG Combinations for the treatment of cancer comprising a mps-1 kinase inhibitor and a mitotic inhibitor
EP2860177A3 (en) 2013-09-20 2015-06-10 Bayer Intellectual Property GmbH Synthesis of functionalized arenes
EP3145928B1 (en) * 2014-05-19 2019-12-04 UDC Ireland Limited Fluorescent organic light emitting elements having high efficiency
MA41136A (fr) * 2014-12-09 2017-10-17 Bayer Pharma AG Composés pour le traitement d'un cancer
WO2016096610A1 (de) 2014-12-15 2016-06-23 Bayer Pharma Aktiengesellschaft Antikörper-wirkstoff-konjugate (adcs) von ksp-inhibitoren mit aglycosylierten anti-tweakrantikörpern
CN105985241A (zh) * 2015-01-27 2016-10-05 邵阳学院 α-取代苯乙酸酯类化合物α-糖苷酶抑制作用及其应用
US20180318438A1 (en) 2015-06-23 2018-11-08 Bayer Pharma Aktiengesellschaft Antibody drug conjugates of kinesin spindel protein (ksp) inhibitors with anti-tweakr-antibodies
WO2017060322A2 (en) 2015-10-10 2017-04-13 Bayer Pharma Aktiengesellschaft Ptefb-inhibitor-adc
EP3471776B1 (en) 2016-06-15 2022-05-04 Bayer Pharma Aktiengesellschaft Specific antibody-drug-conjugates with ksp inhibitors and anti-cd123-antibodies
TW201800408A (zh) 2016-06-15 2018-01-01 拜耳製藥公司 Mps-1抑制劑
CN110248937B (zh) * 2016-10-27 2022-03-29 拜耳股份有限公司 4,5-环状1,2,4-三唑酮
JP7066714B2 (ja) 2016-12-21 2022-05-13 バイエル・ファルマ・アクティエンゲゼルシャフト 酵素的に切断可能な基を有する抗体薬物コンジュゲート（ａｄｃ）
JP7030811B2 (ja) 2016-12-21 2022-03-07 バイエル・ファルマ・アクティエンゲゼルシャフト Ｋｓｐ阻害剤を有する特異的抗体－薬物コンジュゲート（ａｄｃ）
CN106831555B (zh) * 2017-01-22 2019-09-24 中国农业大学 吡啶酰胺类化合物及其制备方法与应用
KR20200011060A (ko) 2018-07-23 2020-02-03 삼성디스플레이 주식회사 유기 발광 소자
WO2020161257A1 (en) 2019-02-07 2020-08-13 Bayer Aktiengesellschaft 3-amino-2-[2-(acylamino)pyridin-4-yl]-1,5,6,7-tetrahydro-4h-pyrrolo[3,2-c]pyridin-4-one as csnk1 inhibitors
JP7266441B2 (ja) 2019-02-15 2023-04-28 三星ディスプレイ株式會社 有機発光素子、及びそれを含んだ電子装置
KR20210059153A (ko) 2019-11-14 2021-05-25 삼성디스플레이 주식회사 유기 발광 소자 및 이를 포함한 장치
WO2023167549A1 (en) * 2022-03-04 2023-09-07 Sillajen, Inc. Pharmaceutical combinations for use in the treatment of neoplastic diseases

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
US6693116B2 (en) * 2001-10-08 2004-02-17 Hoffmann-La Roche Inc. Adenosine receptor ligands
CA2530679A1 (en) 2003-06-30 2005-04-07 Hif Bio, Inc. Compounds for treating angiogenesis
WO2007065010A2 (en) 2005-12-02 2007-06-07 Hif Bio, Inc. Anti-angiogenesis compounds
EP2057158B8 (en) * 2006-08-30 2015-09-30 Cellzome Limited Triazole derivatives as kinase inhibitors
US8053574B2 (en) 2007-07-18 2011-11-08 Novartis Ag Organic compounds
WO2009024824A1 (en) 2007-08-23 2009-02-26 Astrazeneca Ab 2-anilinopurin-8-ones as inhibitors of ttk/mps1 for the treatment of proliferative disorders
US8263595B2 (en) 2007-08-31 2012-09-11 Merck Serono Sa Triazolopyridine compounds and their use as ask inhibitors
GB0719803D0 (en) 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
UA102828C2 (en) 2007-11-27 2013-08-27 Целльзом Лимитед Amino triazoles as p13k inhibitors
WO2010092015A1 (en) 2009-02-10 2010-08-19 Cellzome Limited Urea triazololo [1, 5-a] pyridine derivatives as pi3k inhibitors
SG173610A1 (en) 2009-02-13 2011-09-29 Fovea Pharmaceuticals Sa [1, 2, 4] triazolo [1, 5 -a] pyridines as kinase inhibitors
WO2010124826A1 (en) 2009-04-29 2010-11-04 Bayer Schering Pharma Aktiengesellschaft Substituted imidazoquinoxalines
US9340528B2 (en) 2009-09-04 2016-05-17 Bayer Pharma Aktiengesellschaft Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors
EP2343294A1 (en) * 2009-11-30 2011-07-13 Bayer Schering Pharma AG Substituted triazolopyridines
EP2343297A1 (en) * 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridines
EP2343295A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridine derivates
CN102803261A (zh) 2010-01-15 2012-11-28 杨森制药公司 作为γ分泌酶调节剂的新的取代的双环三唑衍生物
US20110190269A1 (en) 2010-02-01 2011-08-04 Karlheinz Baumann Gamma secretase modulators
JP2011246389A (ja) * 2010-05-26 2011-12-08 Oncotherapy Science Ltd Ｔｔｋ阻害作用を有する縮環ピラゾール誘導体
UY33452A (es) * 2010-06-16 2012-01-31 Bayer Schering Pharma Ag Triazolopiridinas sustituidas
AP3491A (en) * 2011-04-21 2015-12-31 Bayer Ip Gmbh Triazolopyridines

Also Published As

Publication number Publication date
PE20141597A1 (es) 2014-11-07
PL2791136T3 (pl) 2015-12-31
HK1203200A1 (en) 2015-10-23
IL232930A (en) 2016-07-31
UY34515A (es) 2013-07-31
US9663510B2 (en) 2017-05-30
EP2791136B1 (en) 2015-07-29
DK2791136T3 (en) 2015-10-26
NZ625815A (en) 2016-07-29
CA2858683A1 (en) 2013-06-20
AR089143A1 (es) 2014-07-30
HRP20151103T1 (en) 2015-11-20
BR112014014184A2 (pt) 2017-06-13
MA35826B1 (fr) 2014-12-01
JO3111B1 (ar) 2017-09-20
PT2791136E (pt) 2015-11-04
CY1116958T1 (el) 2017-04-05
RU2632464C1 (ru) 2017-10-05
SG11201402820SA (en) 2014-06-27
UA112096C2 (uk) 2016-07-25
ES2550677T3 (es) 2015-11-11
KR20140105552A (ko) 2014-09-01
ECSP14004812A (es) 2015-11-30
PH12014501319A1 (en) 2014-09-08
WO2013087579A1 (en) 2013-06-20
MX2014007057A (es) 2014-08-08
CL2014001546A1 (es) 2014-10-24
CN104114552A (zh) 2014-10-22
TN2014000254A1 (en) 2015-09-30
JP2015500308A (ja) 2015-01-05
SI2791136T1 (sl) 2015-11-30
CO6980657A2 (es) 2014-06-27
JP6181664B2 (ja) 2017-08-16
AP4017A (en) 2017-01-28
AP2014007731A0 (en) 2014-06-30
HUE025937T2 (en) 2016-05-30
US20150210683A1 (en) 2015-07-30
CR20140275A (es) 2014-08-13
CU20140068A7 (es) 2014-12-26
RS54288B1 (en) 2016-02-29
AU2012350751B2 (en) 2017-07-06
AU2012350751A1 (en) 2014-06-26
ZA201404031B (en) 2016-09-28
GT201400111A (es) 2015-11-30
EP2791136A1 (en) 2014-10-22
CN104114552B (zh) 2016-12-28
IL232930A0 (en) 2014-08-03

Similar Documents

Publication Publication Date Title
DOP2014000133A (es) Triazolopiridinas sustituidas
DOP2013000244A (es) Triazolopiridinas
ECSP12011935A (es) Triazolopiridinas
ECSP12012338A (es) Triazolopiridinas sustituidas
CY1124855T1 (el) 2-(μορφολιν-4-υλ)-1,7-ναφθυριδινες
NI201500142A (es) Derivados de 3-acetilamino-1 (fenil-heteroaril-aminocarbonil o fenil-heteroaril-carbonilamino) benceno para el tratamiento de desordenes hiperproliferativos.
UY35040A (es) Pirrolopirimidinilamino-benzotiazolonas sustituidas
GT201400136A (es) Compuestos y métodos de benzaldehído substituído para su uso en incrementar la oxigenación de los tejidos
UY33183A (es) Compuestos inhibidores de virus flaviviridae, composición farmaceutica que los contiene y su uso en la manufactura de un medicamento
CR20140113A (es) Imidazopiridazinas sustituidas con amino
CR20160016A (es) Pirazolpiridinas sustituidas
UY32153A (es) Inhibidores de piridomidinona de pi13ka(alfa) y mtor
CR20160433A (es) Nuevos compuestos
SV2017005466A (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2
CR20150653A (es) Compuestos nuevos para el tratamiento del cáncer
CL2011003123A1 (es) Compuestos derivados de ciclopentanamida sustituidos; composicion farmaceutica; proceso de obtencion; y uso en el tratamiento o la profilaxis de la diabetes, aterosclerosis, entre otras.
CL2011003355A1 (es) Compuestos derivados de alcoxi-carbonil-amino-alquinil-adenosina ; composición farmacéutica que los comprende; uso del compuesto en la preparación de un medicamento útil para tratar enfermedades autoinmunes, inflamatorias, alérgicas, infecciosas entre otras.
CU20130141A7 (es) Triazolopiridinas
CL2011001916A1 (es) Uso de ezatiostat o una sal de el para el tratamiento del sindrome mielodisplasico; composicion farmaceutica que comprende a dicho compuesto ademas de lenalidomida; combinacion farmaceutica; kit farmaceutico.